You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 新華製藥漲停 H股停牌對A股無影響
格隆匯4月28日丨新華製藥AH股漲跌互現,新華製藥漲停,報12.49元,總市值84億元;山東新華製藥(0719.HK)今早復牌,大幅衝高11%後下挫13%,現跌3.51%,報6.32港元。山東新華製藥股份27日公佈,2022年4月26日,山東新華製藥股份有限公司與河南真實生物科技有限公司簽署《戰略合作協議》,真實生物同意新華製藥為其擁有的阿茲夫定等產品在中國及經雙方同意的其他國家的產品生產商和經銷商。公司在互動平台表示,公司與真實生物雙方達成的只是初步戰略性合作協議,目前尚未簽署任何相關產品的具體合作協議。新華製藥27日公吿,公司於4月27日在香港聯交所網站刊登了《暫停買賣》公吿,公司的H股股份已於4月27日上午11:09時起在香港聯交所短暫停牌,以待公司發出可能涉及公司內幕消息之公吿。H股股份停牌對A股無影響。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.